Home Finance Japan okays Sun’s psoriasis drug

Japan okays Sun’s psoriasis drug

Japan okays Sun’s psoriasis drug


Sun Pharma Japan, a wholly owned subsidiary of Sun Pharmaceutical Industries, has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 4,30,000 people currently suffering from psoriasis.

Junichi Nakamichi, country head, Sun Pharma Japan, said, “ILUMYA is the first innovative drug that Sun Pharma plans to launch in Japan. It was extensively tested in Japanese patients as part of ILUMYA’s global clinical development programme.”

“The drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle everyday with the chronic nature of plaque psoriasis. It showed sustained efficacy for over four years and has safety profiles over four years with low rates of severe infections, malignancies and MACEs,” he added.

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by the USFDA in March 2018 while the European Commission approved it in September 2018. The MHLW approval of ILUMYA for the treatment of plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development programme, the company said in a statement.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.



Source Name – The Hindu